Dermatology Reports https://www.pagepress.org/journals/index.php/dr <p><strong>Dermatology Reports</strong> is an online-only, international, Open Access peer-reviewed journal which publish scientific papers about skin diseases. Manuscripts dealing with research, biology,&nbsp;epidemiology,&nbsp;clinics of all skin-related diseases are welcome.&nbsp;<strong>Dermatology Reports</strong> publishes original&nbsp;articles, reviews, brief reports and case reports.</p> en-US <p><strong>PAGEPress</strong> has chosen to apply the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener"><strong>Creative Commons Attribution NonCommercial 4.0 International License</strong></a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.<br><br> An Open Access Publication is one that meets the following two conditions:</p> <ol> <li>the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li> <li>a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li> </ol> <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</li> </ol> francesca.baccino@pagepress.org (Francesca Baccino) tiziano.taccini@pagepress.org (Tiziano Taccini) Mon, 01 Oct 2018 12:11:43 +0200 OJS 3.1.1.4 http://blogs.law.harvard.edu/tech/rss 60 Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data https://www.pagepress.org/journals/index.php/dr/article/view/7859 Hidradenitis suppurativa (HS) is a relapsing, inflammatory disease characterized by painful nodules, abscesses, sinuses track formation and scarring. HS has a great impact on patients’ quality of life and its treatment may be really challenging. Adalimumab provides a new therapeutic option for HS. Our aim was to assess the therapeutic potential of adalimumab on patients with HS based on the data from the daily clinical practice of an HS Outpatient Clinic. 19 patients with clinically evident moderate to severe HS, under adalimumab treatment for at least 24 week, participated in this observational, retrospective study. The Hidradenitis Suppurativa Physician’s Global Assessment scale, Modified Santorius scale and Dermatology Life Quality Index (DLQI) at baseline, week 4, week 12 and week 24 were retrieved from the records. Both Modified Santorius score and DLQI were significantly decreased during the weeks of evaluation (Friedman’s test; P &lt; 0.001). The proportion of patients who achieved clinical response was 10.5% (n = 2) at week 4, 42.1% (n = 8) at week 12 and 63.2% (n = 12) at week 24. Treatment with adalimumab was linked with both clinical remission of HS and improvement of patients’ quality of life. Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.pagepress.org/journals/index.php/dr/article/view/7859 Mon, 01 Oct 2018 12:12:45 +0200 Antioxidant properties of topical Caulerpa sp. extract on UVB-induced photoaging in mice https://www.pagepress.org/journals/index.php/dr/article/view/7597 <p><em>Caulerpa sp</em>., a genus of seaweed native to the Indo-Pacific region, has been known for its antioxidant properties and health benefits when consumed as food. Previous studies have reported <em>Caulerpa sp</em>.’s potential as a strong antioxidant, but its effects on the skin in a topical preparation, especially its role in ultraviolet (UV) protection, have not been studied extensively. Our study investigated the protective effects of 0.2% and 0.4% <em>Caulerpa sp</em>. extract gels on photoaging in the UVB-irradiated skin of <em>Wistar</em> mice. The subjects were divided into naive control, vehicle control, and 3 treatment groups (0.2% <em>Caulerpa sp</em>. extract gel, 0.4% <em>Caulerpa sp</em>. extract gel, and 0.02% astaxanthin gel as a standard antioxidant). The groups, except the naive control group, received a total of 840 mJ/cm<sup>2</sup> of UVB irradiation in four weeks. Protective effects of the extract were measured through the evaluation of collagen expression, MMP-1 expression and levels, and 8-OhDG expression. Mice who received topical application of <em>Caulerpa sp</em>. extract gel had higher collagen expression, better-preserved collagen structure, lower levels of MMP-1, and less MMP-1 and 8-OHdG expressions compared to the vehicle control group. There was no difference between different concentrations of the extract. Our findings demonstrated that topical application of <em>Caulerpa sp</em>. extract gel significantly protected UVB-irradiated mice skin from photoaging.</p> Anak Agung Gde Putra Wiraguna, Wimpie Pangkahila, I. Nyoman Mantik Astawa ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.pagepress.org/journals/index.php/dr/article/view/7597 Mon, 01 Oct 2018 12:11:41 +0200 Histopathological and patient-related characteristics of basal cell carcinomas of the head and neck influencing therapeutic management https://www.pagepress.org/journals/index.php/dr/article/view/7674 <p>The authors hypothesize that histopathological characteristics of basal cell carcinomas of the head and neck (BCCHN) have changed over time and the correlation of BCCHN localization and histological tumour type can help improving the number and quality of necessary therapeutic interventions. Information of 222 patients with 344 BCCHN was gained. Descriptive measures were compared to prior studies to prove whether or not characteristics of basal cell carcinomas or patients have changed over time. Afterwards descriptive measures were correlated with number of conducted operations to evaluate if tumour localization, histological tumour type and number of operations depend on one another. Aggravating factors which lead to a higher number of operations were older age, greater size of BCCHN, adjacent elastosis, the localizations eye, ear and nose and histological tumour types <em>morpheaform</em> and <em>nodularulcerated</em>. In comparison to earlier studies characteristics of BCCHN and patients showed positive developments because of grown awareness of BCCHN. Furthermore, our correlations demonstrate that therapeutic results of BCCHN treatment are continuously improving. Nevertheless, treatment of aggressive morpheaform BCCHN in combination with distinctive patient characteristics still needs improvement.</p> Henrik Holtmann, Vera Fuhrmann, Karoline Sander, Christoph Sproll, Norbert R. Kübler, Daman Deep Singh, Julian Lommen ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.pagepress.org/journals/index.php/dr/article/view/7674 Tue, 04 Dec 2018 10:03:04 +0100 Lupus pernio (Besnier-Tenneson syndrome): A rare form of sarcoidosis https://www.pagepress.org/journals/index.php/dr/article/view/7696 Lupus pernio (LP) is a chronic non-life threatining type of cutaneous sarcoidosis that can be related to chronic fibrotic sarcoidosis, hyperglobulinemia and hypercalcemia. The aim of this case report is to evaluate the clinical and demographic features of cutaneous sarcoidosis mainly presenting with a rare manifestation of LP. In this paper we report a case of systemic sarcoidosis presenting with LP and a review of the available literature. LP is a rare presentation with infiltrated erythematoviolaceous plaques affecting the nose. We address the main management approach, and possible association with an underlying systemic sarcoidosis. LP is a rare but chronic manifestation of systemic sarcoidosis that needs to be treated in order to prevent cosmetic defects and psychological effects. It is important to recognize such a condition early in order to avoid a delay in treatment and worsening of the condition, both physically and psychologically. Further research regarding the diagnostic approach and management is required to understand this condition thoroughly. Amal Hubail, Roza Belkharoeva, Natalya Tepluk, Tatyana Belerosova ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.pagepress.org/journals/index.php/dr/article/view/7696 Mon, 01 Oct 2018 12:11:42 +0200 Cephalexin-induced acute generalized exanthematous pustulosis https://www.pagepress.org/journals/index.php/dr/article/view/7686 Cephalexin is a cephalosporin antibiotic that is commonly used in the treatment of infectious diseases. We report a patient exhibiting a rare adverse effect of cephalexin: drug-induced Acute Generalized Exanthematous Pustulosis (AGEP). We present this case because of the scarcity of reports associating cephalexin with AGEP in hopes that clinicians will consider AGEP in their differential diagnosis in the appropriate clinical setting. Matthew DaCunha, Sarah Moore, David Kaplan ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.pagepress.org/journals/index.php/dr/article/view/7686 Mon, 01 Oct 2018 12:11:42 +0200